The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Aug 2019
Price : $35 *
At a glance
- Drugs Eculizumab (Primary) ; Antithymocyte globulin
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Acronyms DUET
- 20 Aug 2019 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
- 20 Aug 2019 Planned primary completion date changed from 1 Dec 2018 to 30 Aug 2019.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.